Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoSep personalized immunotherapy in sepsis
NL-OMON51161Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jun 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anakinra and interferon gamma-1b in sepsis (4 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Mean total SOFA score through day 9. Started Jun 2022; status: completed.
02
Drugs
anakinrainterferon gamma-1b
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON51161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51161.